Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2011
Business Overview: Accuray designs and sells advanced medical radiation systems for cancer treatment, primarily the CyberKnife® Robotic Radiosurgery System and the TomoTherapy® System. On June 10, 2011, Accuray completed the acquisition of TomoTherapy Incorporated for approximately $248 million in cash and stock, making it a wholly-owned subsidiary. The company operates globally with significant revenue derived from international markets (45% of total revenue in 2011).
Key Financial Metrics
| Metric | Fiscal 2011 | Fiscal 2010 |
|---|---|---|
| Net Revenue | $222.3 million | $221.6 million |
| Gross Profit | $107.2 million (48.2% margin) | $104.0 million (46.9% margin) |
| Operating Loss | $(28.3) million | $2.8 million (Income) |
| Net Loss Attributable to Stockholders | $(26.7) million | $2.8 million (Income) |
| Cash and Cash Equivalents | $95.9 million | $45.4 million |
| Total Assets | $455.8 million | $263.2 million |
| Working Capital | $82.7 million | $152.0 million |
| Accumulated Deficit | $(144.4) million | $(117.7) million |
Note: Fiscal 2011 results include approximately $11.1 million of revenue from TomoTherapy for the period following the June 10 acquisition.
Material Changes vs. Prior Period
- Acquisition Impact: The primary driver of financial changes was the acquisition of TomoTherapy. This resulted in a significant increase in total assets (primarily goodwill and intangible assets) and a sharp rise in operating expenses due to acquisition-related costs (severance, legal, accounting, integration) totaling approximately $18.5 million.
- Profitability Reversal: The company shifted from a net income of $2.8 million in 2010 to a net loss of $26.7 million in 2011. This was driven by a $21.2 million increase in General and Administrative expenses and a $10.2 million increase in Research and Development expenses, largely attributable to the TomoTherapy acquisition and integration.
- Revenue Stability: Despite the acquisition, total net revenue remained relatively flat ($222.3M vs $221.6M). Product revenue decreased slightly ($138.6M vs $143.2M) due to the decline in revenue from the legacy "Platinum" service plan, while service revenue increased ($80.5M vs $77.5M) due to the growing installed base and the addition of TomoTherapy services.
- Liquidity: Cash and cash equivalents more than doubled to $95.9 million, supported by net cash provided by operating activities ($12.4 million) and investing activities ($31.4 million), partially offset by the $70.3 million cash used for the TomoTherapy acquisition.
Guidance, Outlook, Risks, and Contingencies
- Internal Control Material Weakness: Management and the independent auditor (Grant Thornton LLP) identified a material weakness in internal control over financial reporting. The weakness related to the accounting for significant, non-routine transactions, specifically the lack of sufficient skilled accountants to timely analyze the TomoTherapy acquisition. This resulted in an adverse opinion on internal controls.
- Outlook: Management expects selling, marketing, R&D, and G&A expenses to increase in fiscal 2012 due to the integration of TomoTherapy. The company anticipates the acquisition will be accretive to earnings per share in fiscal 2012, though this is subject to realization of synergies.
- Debt Financing: Subsequent to the fiscal year end (August 1, 2011), the company issued $100 million of 3.75% Convertible Senior Notes due 2016, receiving net proceeds of approximately $96.3 million.
- Legal Contingencies:
- Securities Litigation: A securities class action lawsuit was settled for $13.5 million (covered by insurance). A shareholder derivative action was settled for $0.8 million (covered by insurance).
- Patent Litigation: Best Medical International is pursuing patent infringement claims. The court dismissed most counts, leaving one patent at issue. The financial impact is currently indeterminable.
- Trade Secrets: Best Medical International filed a trade secret lawsuit; the company is awaiting a ruling on a summary judgment motion.
- Regulatory Risks: The company faces risks related to FDA 510(k) clearance for product modifications and potential changes in Medicare reimbursement rates, which could impact customer purchasing decisions.
Key Facts for Investor Verification
- Integration Success: Verify the company's ability to successfully integrate TomoTherapy operations and realize anticipated cost synergies to offset the significant acquisition-related expenses incurred in 2011.
- Internal Control Remediation: Monitor the progress of hiring additional skilled accountants and remediation efforts to address the material weakness in internal controls, which currently carries an adverse audit opinion.
- Reimbursement Environment: Assess the impact of proposed Medicare rate reductions for radiation therapy and radiosurgery on future order volumes and revenue recognition.
- Convertible Notes: Evaluate the impact of the $100 million convertible senior notes issued in August 2011 on future liquidity, interest obligations, and potential equity dilution.
- Backlog Conversion: Review the conversion rate of the reported backlog ($288.5 million product-only backlog as of June 30, 2011) into recognized revenue, considering potential customer financing delays or cancellations.